Net sales surged 165% in Q2 2025, driven by ES-Medical, while operating losses narrowed significantly. Acquisition activity is accelerating, with a major deal in progress and legacy assets divested for 10 MSEK. Financing is secured via a 25 MSEK facility.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.